Eli Lilly and Co. LLY
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NYSE · United States · lilly.com
Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana, that discovers, develops, manufactures, and markets medicines across therapeutic areas including diabetes, obesity, oncology, immunology, and neuroscience. Its leading products include Mounjaro and Zepbound (tirzepatide) for diabetes and obesity, Verzenio for breast cancer, and Taltz for autoimmune conditions. Lilly operates in more than 125 countries and invests heavily in research and development.
Key ratios
FreeCashFlowOnSale TTM 0.14
FreeCashFlowOnSale 2025 0.14
FreeCashFlowOnSale 2024 0.08
FreeCashFlowOnSale 2023 0.02
NetIncomeMargin TTM 0.32
NetIncomeMargin 2025 0.32
NetIncomeMargin 2024 0.24
NetIncomeMargin 2023 0.15
ReturnOnAssets TTM 0.19
ReturnOnAssets 2025 0.19
ReturnOnAssets 2024 0.15
ReturnOnAssets 2023 0.11
ReturnOnEquity TTM 1.01
ReturnOnEquity 2025 1.01
ReturnOnEquity 2024 0.84
ReturnOnEquity 2023 0.48
Recent news
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
2026-06-26 · PR Newswire
Lilly declares third-quarter 2026 dividend
2026-06-22 · PR Newswire